CNTA Centessa Pharmaceuticals plc
Healthcare$39.75-0.15%ClosedMarket Cap: $6.15B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
12.52
P/S
0.00
EV/EBITDA
-22.93
DCF Value
$0.70
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.4%
ROA
-39.1%
ROIC
-42.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-79.8M | $-79.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-68.5M | $-66.2M | $— | — |
| FY null | $15.0M | 100.0% | $-207.7M | $-197.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-53.8M | $-54.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-54.7M | $-50.3M | $— | — |
| Q1 null | $15.0M | 100.0% | $-30.8M | $-26.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-74.6M | $-111.3M | $— | — |
| FY null | $0.00 | NaN% | $-201.1M | $-235.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-46.4M | $-42.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-44.0M | $-43.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-36.1M | $-38.0M | $— | — |
| Q4 2023 | $6.9M | 100.0% | $-35.2M | $-36.8M | $-0.38 | — |